Aurélien Marabelle, MD, PhD, clinical director of the Cancer Immunotherapy Program at Gustave Roussy Cancer Center, discusses preliminary findings from a trial examining SO-C101 in patients with advanced solid tumors. 

Initial findings from an ongoing phase 1/1b trial (NCT04234113), which evaluated SO-C101 as a monotherapy and in combination with pembrolizumab (Keytruda) in patients with advanced or metastatic solid tumors, were presented during the 2020 SITC Annual Meeting. SO-C101 demonstrated encouraging efficacy signals with a manageable safety profile in 1 patient who was refractory to anti–PD-1 therapy. The patient derived a partial response to the treatment with 20% shrinkage of target lesions at 6 weeks and 49% shrinkage at 12 weeks. 

These findings suggest that SO-C101 could have clinical utility in patients who are refractory to anti–PD-1 therapy, says Marabelle. Moreover, SO-C101 has the potential to reverse PD-1 inhibitor resistance by amplifying a patient’s antitumor immune response, he adds.

These results corroborated preclinical findings and suggest an additional signal that cytokine therapies beyond interleukin-15 are promising, Marabelle explains. Further research is needed to determine the optimal use of these agents with regard to sequencing, dosing, and timing of infusions, concludes Marabelle.

Videos

Aurélien Marabelle, MD, PhD, discusses preliminary findings from a trial examining SO-C101 in patients with advanced solid tumors.  


Aurélien Marabelle, MD, PhD

Articles

Dr. Marabelle on Preliminary Findings With SO-C101 in Advanced Solid Tumors